Genistein aglycone: A new therapeutic approach to reduce endometrial hyperplasia

Phytomedicine

Volumn 17, Issue 11, 2010, Pages 844-850

  Bitto, Alessandra ^a   Granese, Roberta ^a   Triolo, Onofrio ^a   Villari, Daniela ^a   Maisano, Daniele ^a   Giordano, Domenico ^a   Altavilla, Domenica ^a   Marini, Herbert ^a   Adamo, Elena Bianca ^a   Nicotina, Piero Antonio ^a   D'Anna, Rosario ^a   Squadrito, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Endometrial hyperplasia; Estrogen receptor beta 1; Genistein aglycone; Hysteroscopy

Indexed keywords

AGLYCONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLITROPIN; GENISTEIN; GENISTEIN AGLYCONE; LUTEINIZING HORMONE; NORETHISTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FEMALE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTENSION; HYSTEROSCOPY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; UTERINE CERVIX BIOPSY; VAGINA BLEEDING; WATER RETENTION;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; GENISTEIN; HUMANS; MIDDLE AGED; NORETHINDRONE; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; UTERINE HEMORRHAGE;

EID: 77955980256     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2010.03.024     Document Type: Article

References (53)

1. Agorastos T., Vaitsi V., Pantazis K., Efstathiadis E., Vavilis D., Bontis J.N. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 118:239-240.
2. Allison K.H., Reed S.D., Voigt L.F., Jordan C.D., Newton K.M., Garcia R.L. Diagnosing Endometrial Hyperplasia: why is it so difficult to agree?. Am. J. Surg. Pathol. 2008, 32:691-698.
3. Atteritano M., Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Mazzaferro S., D'Anna R., Cannata M.L., Gaudio A., Frisina A., Frisina N., Corrado F., Cancellieri F., Lubrano C., Bonaiuto M., Adamo E.B., Squadrito F. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2007, 92:3068-3075.
4. Atteritano M., Pernice F., Mazzaferro S., Mantuano S., Frisina A., D'Anna R., Cannata M.L., Bitto A., Squadrito F., Frisina N., Buemi M. Effects of phytoestrogen genistein on cytogenetic biomarkers in postmenopausal women: 1 year randomized, placebo-controlled study. Eur. J. Pharmacol. 2008, 589:22-26.
5. Baggish M.S., Barbot J., Valle R.F. Diagnostic and Operative Hysteroscopy. A Text and Atlas 1988, Saunders, Philadelphia.
6. Ballard-Barbash R., Swanson C.A. Body weight: estimation of risk for breast and endometrial cancers. Am. J. Clin. Nutr. 1996, 63:437S-441S.
7. Ballaré C., Vallejo G., Vicent G.P., Saragüeta P., Beato M. Progesterone signaling in breast and endometrium. J. Steroid. Biochem. Mol. Biol. 2006, 102:2-10.
8. Bitto A., Minutoli L., Squadrito F., D'Anna R., Polito F., Altavilla D. Genistein administration and climacteric symptoms: from plasma levels to biological activity. Indian J. Med. Res. 2007, 125:508-509.
9. Bombail V., MacPherson S., Critchley H.O., Saunders P.T. Estrogen receptor related beta is expressed in human endometrium throughout the normal menstrual cycle. Hum. Reprod. 2008, 23:2782-2790.
10. Brueggemeier R.W., Gu X., Mobley J.A., Joomprabutra S., Bhat A.S., Whetstone J.L. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis and metabolism. Ann. N.Y. Acad. Sci. 2001, 13:261-272.
11. Buemi M., Allegra A., Corica F., D'Anna R., Ruello A., Jasonni V.M. B cell leukaemia/lymphoma-2 protein concentrations during normal pregnancy. BJOG 2000, 107:133-134.
12. Cabanes A., Wang M., Olivo S., DeAssis S., Gustafsson J.A., Khan G., Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 2004, 25:741-748.
13. Cappelletti V., Miodini P., Di Fronzo G., Daidone M.G. Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. Int. J. Oncol. 2006, 28:1185-1191.
14. Cline J.M., Paschold J.C., Anthony M.S., Obasanjo I.O., Adams M.R. Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques. Fertil. Steril. 1996, 65:1031-1035.
15. Cotroneo M.S., Wang J., Eltoum I.E.A., Lamartiniere C.A. Sex steroid receptor regulation by genistein in the prepubertal rat uterus. Mol. Cell. Endocrinol. 2001, 173:135-145.
16. Crisafulli A., Altavilla D., Marini H., Bitto A., Cucinotta D., Frisina N., Corrado F., D'Anna R., Squadrito G., Adamo E.B., Marini R., Romeo A., Cancellieri F., Buemi M., Squadrito F. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 2005, 12:186-192.
17. Crisafulli A., Marini H., Bitto A., Altavilla D., Squadrito G., Romeo A., Adamo E.B., Marini R., D'Anna R., Corrado F., Bartolone S., Frisina N., Squadrito F. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause 2004, 11:400-404.
18. Critchley H.O., Henderson T.A., Kelly R.W., Scobie G.S., Evans L.R., Groome N.P., Saunders P.T. Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J. Clin. Endocrinol. Metab. 2002, 87:5265-5273.
19. Dang Z.C., Audinot V., Papapoulos S.E., Boutin J.A., Löwik C.W. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 2003, 278:927-962.
20. D'Anna R., Cannata M.L., Atteritano M., Cancellieri F., Corrado F., Baviera G., Triolo O., Antico F., Gaudio A., Frisina N., Bitto A., Polito F., Minutoli L., Altavilla D., Marini H., Squadrito F. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized,double-blind, placebo-controlled study. Menopause 2007, 14(4):648-655.
21. D'Anna R., Cannata M.L., Marini H., Atteritano M., Cancellieri F., Corrado F., Triolo O., Rizzo P., Russo S., Gaudio A., Frisina N., Bitto A., Polito F., Minutoli L., Altavilla D., Adamo E.B., Squadrito F. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause 2009, 16:301-306.
22. Fan S., Meng Q., Auborn K., Carter T., Rosen E.M. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br. J. Cancer 2006, 94:407-426.
23. Frech M.S., Halama E.D., Tilli M.T., Singh B., Gunther E.J., Chodosh L.A., Flaws J.A., Furth P.A. Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res. 2005, 65:681-685.
24. Garcia, F., Chambers, S.K., 2008. Fundamentals of cancer prevention. In: Endometrial Cancer Prevention, pp. 475-494.
25. Guruwadayarhalli B., Jones S.E., Srinivasan V. Hysteroscopy in the diagnosis of postmenopausal bleeding. Menopause Int. 2007, 13:132-134.
26. Hall J.M., McDonnell D.P. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ER transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140:5566-5578.
27. Horn L.C., Schnurrbusch U., Bilek K., Hentschel B., Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestin treatment. Int. J. Gynecol. Cancer 2004, 14:348-353.
28. Inoue S., Ogawa S., Horie K., Hoshino S., Goto W., Hosoi T., Tsutsumi O., Muramatsu M., Ouchi Y. An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and Erbeta. Biochem. Biophys. Res. Commun. 2000, 279:814-819.
29. Kuiper G.G. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors β and α. Endocrinology 1997, 138:863-869.
30. Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 subjects. Cancer 1985, 56:403-412.
31. Lai C.H., Huang H.J. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr. Opin. Obstet. Gynecol. 2006, 18:29-34. Review.
32. Lamartiniere C.A. Protection against breast cancer with genistein: a component of soy. Am. J. Clin. Nutr. 2000, 71:1705S-1707S.
33. Linkov F., Edwards R., Balk J., Yurkovetsky Z., Stadterman B., Lokshin A., Taioli E. Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk factors. Eur. J. Cancer 2008, 44:1632-1644.
34. Marini H., Bitto A., Altavilla D., Burnett B.P., Polito F., Di Stefano V., Minutoli L., Atteritano M., Levy R.M., D'Anna R., Frisina N., Mazzaferro S., Cancellieri F., Cannata M.L., Corrado F., Frisina A., Adamo V., Lubrano C., Sansotta C., Marini R., Adamo E.B., Squadrito F. Breast safety and efficacy of genistein aglycone for post-menopausal bone loss: a follow-up study. J. Clin. Endocrinol. Metab. 2008, 93:4787-4796.
35. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M., Gaudio A., Mazzaferro S., Frisina A., Frisina N., Lubrano C., Bonaiuto M., D'Anna R., Cannata M.L., Corrado F., Cancellieri F., Faraci M., Marini R., Adamo E.B., Wilson S., Squadrito F. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J. Bone Miner. Res. 2008, 23:715-720.
36. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M., Gaudio A., Mazzaferro S., Frisina A., Frisina N., Lubrano C., Bonaiuto M., D'Anna R., Cannata M.L., Corrado F., Adamo E.B., Wilson S., Squadrito F. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann. Intern. Med. 2007, 146:839-847.
37. McCarty M.F. Isoflavones made simple - genistein's agonist activity for the beta-type estrogen receptor mediates their health benefits. Med. Hypotheses 2006, 66:1093-1114.
38. Omoto Y., Eguchi H., Yamamoto-Yamaguchi Y., Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 2003, 22:5011-5020.
39. Ørbo A., Arnes M., Hancke C., Vereide A.B., Pettersen I., Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol. Oncol. 2008, 111:68-73.
40. Purdie D.M. Epidemiology of endometrial cancer. Rev. Gynecol. Pract. 2003, 3:217-220.
41. Romer T. Benefit of GnRH analogue pre-treatment for hysteroscopic surgery in patients with bleeding disorders. Gynecol. Obstet. Invest. 1998, 45:12-20.
42. Skrzypczak M., Bieche I., Szymczak S., Tozlu S., Lewandowski S., Girault I., Radwanska K., Szczylik C., Jakowicki J.A., Lidereau R., Kaczmarek L. Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int. J. Cancer 2004, 110:783-787.
43. Staar S., Richter D.U., Makovitzky J., Briese V., Bergemann C. Stimulation of endometrial glandular cells with genistein and daidzein and their effects on ERalpha- and ERbeta-mRNA and protein expression. Anticancer Res. 2005, 25:1713-1718.
44. Steiner C., Arnould S., Scalbert A., Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br. J. Nutr. Suppl. 2008, 1:ES78-108.
45. Ström A., Hartman J., Foster J.S. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1566-1571.
46. Tamaoka Y., Orikasa H., Sumi Y., Sakakura K., Kamei K., Nagatani M., Ezawa S. Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study. Gynecol. Obstet. Invest. 2004, 58:42-48.
47. Taylor C.K., Levy R.M., Elliott J.C., Burnett B.P. Genistein Effect on Cancer and Cancer Risk: A review of in vitro, preclinical and clinical studies. Nutr. Rev. 2009, 67:398-415.
48. Telner D.E., Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. Can. Fam. Physician. 2007, 53:58-64.
49. Vereide A.B., Kaino T., Sager G., Arnes M., Ørbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol. Oncol. 2006, 101:214-223.
50. Vilos G.A., Lefebvre G., Graves G.R. Guidelines for the management of abnormal uterine bleeding. J. Obstet. Gynaecol. Can. 2001, 23:704-709.
51. Vissac-Sabatier C., Coxam V., Déchelotte P., Picherit C., Horcajada M.N., Davicco M.J., Lebecque P., Bignon Y.J., Bernard-Gallon D. Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor suppressor genes in mammary glands of female Wistar rats. Cancer Res. 2003, 63:6607-6612.
52. Wamsteker K., Emanuel M.H., de Kruif J.H. Transcervical resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet. Gynecol. 1993, 82:736-740.
53. Williamson-Hughes P.S., Flickinger B.D., Messina M.J., Empie M.W. Isoflavone supplements containing predominantly genistein reduce hot flush symptoms: a critical review of published studies. Menopause 2006, 13:831-839.